- Provention Bio (NASDAQ:PRVB) +170% on potential of teplizumab to delay diabetes.
- More news on: Provention Bio, Inc., Tableau Software, Inc., Tilray, Inc., Stocks on the move, Read more ...
Market Wire News is a media platform, the information on this page was provided by SeekingAlpha via Quote Media. Read our full disclaimer.
When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
News, Short Squeeze, Breakout and More Instantly...
Domo (Nasdaq: DOMO) today announced its annual “ Data Never Sleeps ” infographic has been selected as a winner in the Academy of Interactive and Visual Arts (AIVA)’s Communicator Awards for the second consecutive year. For more than a decade, “Data Never Slee...
Today Domo (Nasdaq: DOMO) announced that Medius , a leading accounts payable (AP) software solution provider, utilizes Domo to analyze the impact of its sales and marketing efforts, as well as funnel efficiencies to identify new opportunities that increase sales volume and velocity across...
Domo (Nasdaq: DOMO) today announced it has been named to Parity.Org’s 2024 ParityLIST™ for the fifth consecutive year. The ParityLIST is a program recognizing organizations that are creating the culture and conditions in which all employees have an equal opportunity to compete and...